Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1004 of 6351
-
Could timed light therapy save more premature babies?
Disease control OngoingCycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (\< 750 g BW or \<27 weeks GA).
Sponsor: NICHD Neonatal Research Network • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to shrink lymphoma without chemo
Disease control OngoingThis phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dru…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New pill combo aims to keep advanced breast cancer in check
Disease control OngoingThe purpose of this two part multicenter, randomized, double-blind, placebo-controlled, Phase III study is to evaluate the efficacy and safety of alpelisib compared to alpelisib matching-placebo in combination with trastuzumab and pertuzumab as maintenance treatment of patients w…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare, deadly gynecologic cancers: drug combo trial launches
Disease control Recruiting nowCarcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) \< 10% and a poor…
Phase 2/3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
New drug aimed at folate receptor shows promise for tough endometrial cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Phase 2 • Sponsor: Alessandro Santin • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Stem cell patch shows promise for diabetic foot wounds
Disease control CompletedThis is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Wagner grade 2 Foot Ulcer, compared to placebo therapy.
Phase 3 • Sponsor: Anterogen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for MS patients: ofatumumab cuts relapses in switchers
Disease control CompletedOpen-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy shows promise for advanced skin cancer patients
Disease control CompletedThe purpose of the China Extension study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in Chinese participants with no prior systemic t…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Which procedure wins for dense kidney stones?
Disease control CompletedSeveral studies were conducted to compare extracorporeal shockwave lithotripsy (SWL) and percutaneous nephrolithotomy (PNL) as treatment options for medium size lower caliceal high dense stones. However, no studies compared these options for non- lower polar stones. In the prese…
Sponsor: Al-Azhar University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could deliberate walking errors retrain the brain after stroke?
Disease control CompletedThis three-year study is proposed to document the effect and further implementation of error-augmented walking on gait performance and brain activities in individuals with stroke. Note that brain activations of post-stroke individuals during locomotion is a relatively unexplored …
Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail aims to stall prostate cancer in men with PTEN mutation
Disease control OngoingThis study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTE…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New vaccine shows promise in battling recurrent brain tumors
Disease control CompletedThe purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.
Phase 1/2 • Sponsor: Enterome • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New cocktail of chemo and immunotherapy aims to tame tough cancers
Disease control Recruiting nowThis is an open label, phase II, multi-site trial evaluating the efficacy and safety of the combination of 5-FU, oxaliplatin, nal-IRI, and immunotherapy (plus trastuzumab for HER2-positive tumors) as first-line therapy for participants with advanced Esophageal and Gastric Adenoca…
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Higher dose of muscular dystrophy drug shows promise in new trial
Disease control OngoingPart 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2 (dose finding and dose comparison) will evaluate the efficacy and safety of the high dos…
Phase 3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo aims to outsmart kaposi sarcoma tumors
Disease control Recruiting nowBackground: Kaposi sarcoma (KS) tumors grow on the skin, lymph nodes, lungs, bone, and gastrointestinal tract. KS often affects people with immune deficiencies, such as among people living with HIV or those with prior history of transplant. Researchers want to see if 2 non-chemo…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New combo therapy shows promise in lung cancer battle
Disease control OngoingThis phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of the en…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
New drug combo aims to outperform standard therapy in HER2+ breast cancer
Disease control OngoingThe purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can a DNA vaccine train the immune system to hunt down HER3-Positive cancers?
Vaccine OngoingThis study is a phase I clinical trial will that will use an investigational cancer vaccine called pING-hHER3FL. pING-hHER3FL is a circular piece of DNA that produces the full length human HER3 protein and will be used in a phase I study as immunotherapeutic agent to target cance…
Phase 1 • Sponsor: Herbert Lyerly • Aim: Vaccine
Last updated Sep 04, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood cancers in early trial
Disease control OngoingThis is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research parti…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Promising 4-Drug cocktail aims to deepen remissions in multiple myeloma
Disease control OngoingThis research study is testing the efficacy of an experimental drug combination for people with newly diagnosed multiple myeloma that are eligible for a stem cell transplant. The names of the study drugs involved in this study are: * Carfilzomib * Isatuximab * Lenalidomide * De…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC